Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC
Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.
Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.
Results from the ZN-c3-001, MAMMOTH, and DENALI trials demonstrated meaningful ORRs with azenosertib in platinum-resistant ovarian cancer.
In this issue of Blood, Ikeda and colleagues successfully demonstrated the utility of soluble B-cell maturation antigen (sBCMA) as a quantitative metric fo
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Cancer cases on rise in J&K; Over 12,000 cases being registered every year
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Key PointsRuxolitinib therapy was associated with improvements in lung function for participants with BOS.Clinical responses were more commonly observed in
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
The American Association for Cancer Research (AACR) is increasingly concerned about the numerous executive orders and policy proposals that the new administration has issued during…
Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Registration Type Early Bird Price (October 7, 2024 –…